MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 413877 | Name: Docarpamine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Docarpamine is a dopamine prodrug. The drug does not cross the blood-brain barrier and shows no effect on CNS activity. It is supposed that the drug exerts its action by activating dopamine receptor D1.

Chemical Structure

Docarpamine
Docarpamine
CAS#74639-40-0

Theoretical Analysis

MedKoo Cat#: 413877

Name: Docarpamine

CAS#: 74639-40-0

Chemical Formula: C21H30N2O8S

Exact Mass: 470.1723

Molecular Weight: 470.54

Elemental Analysis: C, 53.60; H, 6.43; N, 5.95; O, 27.20; S, 6.81

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Docarpamine; TA870; TA 870; TA-870
IUPAC/Chemical Name
(-)-(S)-2-Acetamido-N-(3,4-dihydroxyphenethyl)-4-(methylthio)butyramide bis(ethyl carbonate) (ester)
InChi Key
ZLVMAMIPILWYHQ-INIZCTEOSA-N
InChi Code
InChI=1S/C21H30N2O8S/c1-5-28-20(26)30-17-8-7-15(13-18(17)31-21(27)29-6-2)9-11-22-19(25)16(10-12-32-4)23-14(3)24/h7-8,13,16H,5-6,9-12H2,1-4H3,(H,22,25)(H,23,24)/t16-/m0/s1
SMILES Code
O=C(NCCC1=CC=C(OC(OCC)=O)C(OC(OCC)=O)=C1)[C@@H](NC(C)=O)CCSC
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 470.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Yoshikawa M, Nishiyama S, Takaiti O. Metabolism of dopamine prodrug, docarpamine. Hypertens Res. 1995 Jun;18 Suppl 1:S211-3. doi: 10.1291/hypres.18.supplementi_s211. PMID: 8529066. 2: Tsunoda T, Shibahara H, Hirano Y, Suzuki T, Fujiwara H, Takamizawa S, Ogawa S, Motoyama M, Suzuki M. Treatment for ovarian hyperstimulation syndrome using an oral dopamine prodrug, docarpamine. Gynecol Endocrinol. 2003 Aug;17(4):281-6. doi: 10.1080/gye.17.4.281.286. PMID: 14503971. 3: Tano K, Yoshizumi M, Kitagawa T, Hori T, Kitaichi T, Itoh K, Katoh I. Effect of docarpamine, a novel orally active dopamine prodrug, on the formation of free and sulfoconjugated dopamine in patients who underwent cardiac surgery. Life Sci. 1997;61(15):1469-78. doi: 10.1016/s0024-3205(97)00706-6. PMID: 9328226. 4: Funasaki T, Tsutsumi M, Takase S, Tsuchishima M, Ueshima Y, Urashima S, Shimanaka K, Itoh T, Kawahara H. Effects of a new orally active dopamine prodrug, docarpamine, on refractory ascites: a pilot study. Am J Gastroenterol. 1999 Sep;94(9):2475-81. doi: 10.1111/j.1572-0241.1999.01379.x. PMID: 10484011. 5: Watarida S, Shiraishi S, Sugita T, Katsuyama K, Nakajima Y, Yamamoto R, Yamamoto Y, Imura M, Hirokawa R, Mori A. Effects of docarpamine on hemodynamics after open heart surgery in children. Ann Thorac Cardiovasc Surg. 2000 Apr;6(2):106-9. PMID: 10870004. 6: Matsubayashi K, Ueda Y, Ogino H, Sugita T, Sakakibara Y, Matsuyama K, Nomoto T. Oral administration of the dopamine prodrug docarpamine shortens need for drip infusion of dopamine in patients with low cardiac output syndrome after cardiac surgery. Thorac Cardiovasc Surg. 1999 Dec;47(6):352-6. doi: 10.1055/s-2007-1013173. PMID: 10670791. 7: Sanada H, Asico LD, Shigetomi S, Tanaka K, Niimura S, Watanabe H, Goldstein DS, Felder RA. The effect of docarpamine, a dopamine pro-drug, on blood pressure and catecholamine levels in spontaneously hypertensive rats. Clin Exp Hypertens. 2000 May;22(4):419-29. doi: 10.1081/ceh-100100081. PMID: 10830753. 8: Tomita H, Fuse S, Chiba S. Plasma concentration and acute clinical effects of docarpamine, orally active dopamine prodrug, in infants. Acta Paediatr Jpn. 1996 Oct;38(5):440-3. doi: 10.1111/j.1442-200x.1996.tb03523.x. PMID: 8942000. 9: Nishiyama S, Kanno K, Yamaguchi I. Comparison of cardiorenal and emetic effects of dopamine prodrugs docarpamine (TA-870) and levodopa in dogs. J Pharmacobiodyn. 1991 Mar;14(3):120-5. doi: 10.1248/bpb1978.14.120. PMID: 1679131. 10: Doggrell SA. The therapeutic potential of dopamine modulators on the cardiovascular and renal systems. Expert Opin Investig Drugs. 2002 May;11(5):631-44. doi: 10.1517/13543784.11.5.631. PMID: 11996645.